Provides pharmaceutical solutions, including controlled release polymers and tablet coatings. Offers nutrition solutions, such as thickeners, stabilizers, and emulsifiers. Now — the numbers.
Revenue is spread across several lines; no single product carries the company.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 1.8× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 75% of them.
Analysts' average target sits 11% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
The stock has been running stronger than the market lately.
Growth: Sales growth trails the sector average.
The stock trades 38% below its peak. The market has trimmed its expectations for the company.
Over the last 12 months, company executives reported 64 buys and 50 sells. Management buying with its own money is usually read as a good sign.
It pays out $1.67 per share each year — regular cash for whoever holds the stock.
A loss of $845M against $1.8B in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, ASH sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ASH’s sales are going backwards, and it closed last year at a loss. The road back runs through both.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.